<aside>
Neurofibromatosis type 2 (NF2), also known as “Wishart disease” is a rare autosomal dominant neurocutaneous disorder characterized by the development of multiple central and peripheral nervous system tumors, most notably bilateral vestibular schwannomas, which are pathognomonic.
</aside>

Legius E, Ludwine Messiaen, Wolkenstein P, et al. Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation. Genetics in Medicine. 2021;23(8):1506-1513. doi:https://doi.org/10.1038/s41436-021-01170-5
Genetic basis:
| Feature | Description |
|---|---|
| Gene involved | NF2 gene on chromosome 22q12 |
| Protein | Merlin (also called schwannomin) – a tumor suppressor |
| Inheritance | Autosomal dominant (but ~50% are de novo mutations) |
| Tumor predisposition | Loss of merlin function leads to uncontrolled proliferation of Schwann cells and meningeal cells |
| System Involved | Key Manifestations |
|---|---|
| Auditory/Vestibular | Bilateral sensorineural hearing loss, tinnitus, imbalance |
| Cranial nerves | Facial palsy (CN VII), trigeminal neuropathy (CN V) |
| Spinal cord | Schwannomas or intradural extramedullary tumors, ependymomas |
| Eyes | Juvenile cataracts, retinal hamartomas |
| Skin | Few cutaneous neurofibromas, skin plaques (less common than NF1) |
NIH & Manchester Criteria:
| Major criteria | Minor tumors |
|---|---|
| 1. Bilateral vestibular schwannomas (on MRI) |
https://youtu.be/C0_AqYlNRUE?si=I_dtS-Wv3x8fc1as
MRI Brain: